Table of Contents
- Clinical trials overview
- Phase 3 study of Xaluritamig plus abiraterone
- Phase 3 study of Xaluritamig vs cabazitaxel or second androgen receptor-directed therapy
- Main endpoints being measured
- Who may take part
Clinical trials overview
Two authorised Phase 3 trials are studying Xaluritamig in metastatic castration-resistant prostate cancer (mCRPC), which means prostate cancer that has spread and is still growing even after hormone-lowering treatment.[1][2]
Both studies are interventional trials, so the research team assigns the study treatment and compares it with other treatment choices.[1][2]
Phase 3 study of Xaluritamig plus abiraterone
The first trial, 2025-520555-89-00, is a Phase 3 study in chemotherapy-naïve participants with mCRPC, meaning people have not yet received chemotherapy for this cancer.[1]
This study compares Xaluritamig plus abiraterone with the investigator’s choice of docetaxel, cabazitaxel, or abiraterone.[1]
The trial plans to enroll 748 participants and is authorised.[1]
The main goal is to compare overall survival, which means how long people live after starting treatment.[1]
Phase 3 study of Xaluritamig vs cabazitaxel or second androgen receptor-directed therapy
The second trial, NCT06691984, is also a Phase 3 study in people with progressive mCRPC.[2]
This study compares Xaluritamig with investigator’s choice, which can be cabazitaxel or a second androgen receptor-directed therapy such as enzalutamide.[2]
The trial plans to enroll 675 participants and is authorised.[2]
The main outcome is also overall survival.[2]
Main endpoints being measured
The main endpoint in both studies is overall survival, which is the standard way to see whether one treatment helps people live longer than another.[1][2]
Because both trials compare Xaluritamig with other active treatments, they are designed to show whether Xaluritamig can improve outcomes in this advanced prostate cancer setting.[1][2]
Who may take part
These trials are for people with metastatic castration-resistant prostate cancer.[1][2]
One of the studies is specifically for people who have not yet had chemotherapy, while the other is for people with progressive disease after prior treatment choices are being considered.[1][2]
